Review article
Regenerative Medicine with Adult Bone Marrow Derived Stem Cells
Dtsch Arztebl 2007; 104(23): A-1663
; ; ;
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
1. | Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71–4. MEDLINE |
2. | Ferrari G, Cusella-De Angelis G, Coletta M et al.: Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528–30. MEDLINE |
3. | Bjornson CR, Rietze RL, Reynolds BA et al.: Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 1999; 283: 534–7. MEDLINE |
4. | Petersen BE, Bowen WC, Patrene KD et al.: Bone marrow as a potential source of hepatic oval cells. Science 1999; 284: 1168–70. MEDLINE |
5. | Wolff E: Vor 50 Jahren: Paul Niehans bringt den Begriff „Zellulartherapie“ in die Öffentlichkeit. Schweizerische Ärztezeitung 2002; 83: 1726–7. |
6. | Kabelitz D: Nobelpreis für Medizin1990. Dtsch Med Wochenschr 1990; 115: 1927–8. MEDLINE |
7. | Jacobson LO, Simmons EL, Marks EK, Eldredge JH: Recovery from radiation injury. Science 1951; 113: 510–1. MEDLINE |
8. | Spangrude GJ, Heimfeld S, Weissman IL: Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241: 58–62. MEDLINE |
9. | Wagers AJ, Weissman IL: Plasticity of adult stem cells. Cell 2004; 116: 639–48. MEDLINE |
10. | Friedenstein A: Stromal-hematopoietic interrelationships: Maximov's ideas and modern models. Haematol Blood Transfus 1989; 32: 159–67. MEDLINE |
11. | Friedenstein AJ, Petrakova KV, Kurolesova AI et al.: Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230–47. MEDLINE |
12. | Okamoto T, Aoyama T, Nakayama T et al.: Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. Biochem Biophys Res Commun 2002; 295: 354–61. MEDLINE |
13. | Makino S, Fukuda K, Miyoshi S et al.: Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697–705. MEDLINE |
14. | Verfaillie CM: Multipotent adult progenitor cells: an update. Novartis Found Symp 2005; 265: 55–61; discussion 61–55, 92–57. |
15. | Stute N, Holtz K, Bubenheim M et al.: Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol 2004; 32: 1212–25. MEDLINE |
16. | Lange C, Schroeder J, Stute N et al.: High-potential human mesenchymal stem cells. Stem Cells Dev 2005; 14: 70–80. MEDLINE |
17. | D'Ippolito G, Diabira S, Howard GA et al.: Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004; 117: 2971–81. MEDLINE |
18. | Lemischka I: Stem cell dogmas in the genomics era. Rev Clin Exp Hematol 2001; 5: 15–25. MEDLINE |
19. | Lapidot T, Petit I: Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973–81. MEDLINE |
20. | Orlic D, Kajstura J, Chimenti S et al.: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001; 98: 10344–9. MEDLINE |
21. | Fukuhara S, Tomita S, Nakatani T et al.: G-CSF promotes bone marrow cells to migrate into infarcted mice heart, and differentiate into cardiomyocytes. Cell Transplant 2004; 13: 741–8. MEDLINE |
22. | Kawada H, Takizawa S, Takanashi T et al.: Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 2006; 113: 701–10. MEDLINE |
23. | Sesti C, Hale SL, Lutzko C et al.: Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restoring muscle mass. J Am Coll Cardiol 2005; 46: 1662–9. MEDLINE |
24. | Norol F, Merlet P, Isnard R et al.: Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model. Blood 2003; 102: 4361–8. MEDLINE |
25. | Togel F, Isaac J ,Westenfelder C: Hematopoietic stem cell mobilization-associated granulocytosis severely worsens acute renal failure. J Am Soc Nephrol 2004; 15: 1261–7. MEDLINE |
e1. | Harada M, Qin Y, Takano H, et al.: G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005; 11: 305–11. MEDLINE |
e. | 2. Takano H, Qin Y, Hasegawa H, et al.: Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction. J Mol Med 2006; 84: 185–93. MEDLINE |
e3. | Schneider A, Kruger C, Steigleder T, et al.: The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083–98. MEDLINE |
e4. | Joseph J, Rimawi A, Mehta P, et al.: Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. Am J Cardiol 2006; 97: 681–4. MEDLINE |
e5. | Huttmann A, Duhrsen U, Stypmann J, et al.: Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure. Feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol 2006; 101: 78–86. MEDLINE |
e6. | Wang Y, Tagil K, Ripa RS, et al.: Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int J Cardiol 2005; 100: 477–83. MEDLINE |
e7. | Ince H, Petzsch M, Kleine HD, et al.: Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 2005; 112: I73–80. MEDLINE |
e8. | Ripa RS, Jorgensen E, Wang Y, et al.: Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction. Result of the Double-Blind, Randomized, Placebo-Controlled Stem Cells in Myocardial Infarction (STEMMI) Trial. Circulation 2006; 113: 1983–92. MEDLINE |
e9. | Zohlnhofer D, Ott I, Mehilli J, et al.: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295: 1003–10. MEDLINE |
e10. | Buschmann I, Heil M, Jost M, et al.: Influence of inflammatory cytokines on arteriogenesis. Microcirculation 2003; 10: 371–9. MEDLINE |
e11. | Seiler C, Pohl T, Wustmann K, et al.: Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012–7. MEDLINE |
e12. | van Royen N, Schirmer SH, Atasever B, et al.: START Trial: a pilot study on stimulation of arteriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005; 112: 1040–6. MEDLINE |
e13. | Valgimigli M, Rigolin GM, Cittanti C, et al.: Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005; 26: 1838–45. MEDLINE |
e14. | Kuethe F, Figulla HR, Herzau M, et al.: Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 2005; 150: 115. MEDLINE |
e15. | Shyu WC, Lin SZ, Lee CC, et al.: Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ 2006; 174: 927–33. MEDLINE |
e16. | Grigoropoulos NF ,Mathur A: Stem cells in cardiac repair. Curr Opin Pharmacol 2006; 6: 169–75. MEDLINE |
e 17. | Lunde K, Solheim S, Aakhus S, et al.: Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199–209. |
e18. | Janssens S, Dubois C, Bogaert J, et al.: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113–21. MEDLINE |
e19. | Schachinger V, Tonn T, Dimmeler S, et al.: Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. Nat Clin Pract Cardiovasc Med 2006; 3 Suppl 1: S23–8. MEDLINE |
e20. | Meyer GP, Wollert KC, Lotz J, et al.: Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287–94. MEDLINE |
e21. | Tateishi-Yuyama E, Matsubara H, Murohara T, et al.: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427–35. MEDLINE |
e22. | Strauer BE, Brehm M, Zeus T, et al.: Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005; 46: 1651–8. MEDLINE |
e23. | Bartunek J, Vanderheyden M, Vandekerckhove B, et al.: Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005; 112: I178–83. MEDLINE |
e24. | Erbs S, Linke A, Adams V, et al.: Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res 2005; 97: 756–62. MEDLINE |
e25. | Kang HJ, Kim HS, Zhang SY, et al.: Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363: 751–6. |
e26. | Fernandez-Aviles F, San Roman JA, Garcia-Frade J, et al.: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 2004; 95: 742–8. MEDLINE |
e27. | Stamm C, Westphal B, Kleine HD, et al.: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361: 45–6. MEDLINE |
e28. | Tse HF, Kwong YL, Chan JK, et al.: Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47–9. MEDLINE |
e29. | Perin EC, Dohmann HF, Borojevic R, et al.: Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110: II213–8. MEDLINE |
e30. | Wollert KC, Meyer GP, Lotz J, et al.: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141–8. MEDLINE |
e31. | Fuchs S, Kornowski R, Weisz G, et al.: Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 2006; 97: 823–9. MEDLINE |
e32. | Assmus B, Schachinger V, Teupe C, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106: 3009–17. MEDLINE |
e33. | Schachinger V, Assmus B, Britten MB, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690–9. |
e34. | Caplan AI: Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng 2005; 11: 1198–211. MEDLINE |
e35. | Caplan AI: Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells. Connect Tissue Res 1995; 31: S9–14. MEDLINE |
e36. | Caplan AI: Mesenchymal stem cells and gene therapy. Clin Orthop Relat Res 2000: S67–70. MEDLINE |
e37. | Prockop DJ: Targeting gene therapy for osteogenesis imperfecta. N Engl J Med 2004; 350: 2302–4. MEDLINE |
e38. | Prockop DJ, Gregory CA, Spees JL: One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 2003; 100 Suppl 1: 11917–23. MEDLINE |
e39. | Le Blanc K, Frassoni F, Ball L, et al.: Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease. Blood 2005; 106: a143. |
e40. | Le Blanc K, Rasmusson I, Sundberg B, et al.: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–41. MEDLINE |
e41. | Chen SL, Fang WW, Qian J, et al.: Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004; 117: 1443–8. MEDLINE |
e42. | Lazarus HM, Koc ON, Devine SM, et al.: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389–98. MEDLINE |
e43. | Horwitz EM: Marrow mesenchymal cell transplantation for genetic disorders of bone. Cytotherapy 2001; 3: 399–401. MEDLINE |
e44. | Horwitz EM, Gordon PL, Koo WK, et al.: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932–7. MEDLINE |
e45. | Horwitz EM, Prockop DJ, Fitzpatrick LA, et al.: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–13. MEDLINE |
e46. | Lazarus HM, Haynesworth SE, Gerson SL, et al.: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557–64. MEDLINE |
e47. | Koc ON, Gerson SL, Cooper BW, et al.: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–16. MEDLINE |
e48. | MEDLINE Koc ON, Day J, Nieder M, et al.: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215–22. |
e49. | Engelhardt M, Deschler B, Müller C, et al.: Plastizität adulter Stammzellen: Wunschtraum oder Realität? Dtsch Arztebl 2003; 100(49): A 3236–44. VOLLTEXT |
e50. | Kloner RA: Attempts to recruit stem cells for repair of acute myocardial infarction: A dose of reality. JAMA 2006; 295: 1058–60. MEDLINE |
e51. | Assmus B, Honold J, Schächinger V, et al.: Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222–32. MEDLINE |
e52. | Hofmann M, Wollert KC, Meyer GP, et al.: Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198–202. MEDLINE |
e53. | Rosenzweig A. Cardiac cell therapy–mixed results from mixed cells. N Engl J Med 2006; 355: 1274–7. MEDLINE |
e54. | Engelmann MG, Theiss HD and Henning-Theiss C et al., Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006; 48: 1712–21. |
e55. | Chen S, Liu Z, Tian N, et al: Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006; 18: 552–6. MEDLINE |
e51. | Mazzini L, Mareschi K, Ferrero I et al.: Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. 2006; 28: 523–6. MEDLINE |
e56. | Katritsis DG, Sotiropoulou PA, Karvouni E et al: Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005; 65: 321–9. MEDLINE |
e57. | Moviglia GA, Fernandes Vina R, Brizuela JA et al.: Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006; 8: 202–9. MEDLINE |
e58. | Schächinger V, Erbs S, Elsässer A et al.: Improved clinical outcomes after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Europ Heart J 2006; 27: 2775–83. MEDLINE |
e59. | Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874–82. MEDLINE |
e60. | Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31–42. MEDLINE |